ASMB Logo

Assembly Biosciences, Inc. (ASMB) 

NASDAQ
Market Cap
$92.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
124 of 775
Rank in Industry
81 of 433

Largest Insider Buys in Sector

ASMB Stock Price History Chart

ASMB Stock Performance

About Assembly Biosciences, Inc.

Assembly Biosciences, Inc., a clinical-stage biotechnology company, discovers and develops therapeutic candidates for the treatment of hepatitis B virus (HBV) infection in the United States. The company's lead product candidate is Vebicorvir, which as completed Phase 2 clinical trials to treat patients with chronic HBV infection. It is also developing ABI-H3733 that has completed Phase 1a clinical study, and ABI-4334, which is in pre-clinical trials for the treatment of HBV. The company has collaboration agreements with BeiGene, Ltd. and …

Insider Activity of Assembly Biosciences, Inc.

Over the last 12 months, insiders at Assembly Biosciences, Inc. have bought $768,874 and sold $139,156 worth of Assembly Biosciences, Inc. stock.

On average, over the past 5 years, insiders at Assembly Biosciences, Inc. have bought $525,487 and sold $384,013 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Schornstein Alexander (10 percent owner) — $768,695. GILEAD SCIENCES, INC. (10 percent owner) — $718.

The last purchase of 10,000 shares for transaction amount of $145,800 was made by Schornstein Alexander (10 percent owner) on 2024‑10‑08.

List of Insider Buy and Sell Transactions, Assembly Biosciences, Inc.

2024-11-18SaleChief Manufacturing Officer
40
0.0006%
$16.29$652-1.96%
2024-10-08Purchase10 percent owner
10,000
0.1478%
$14.58$145,800+16.57%
2024-10-03SaleCEO and President
197
0.003%
$14.81$2,918+13.96%
2024-10-03SaleChief Manufacturing Officer
157
0.0024%
$14.81$2,325+13.96%
2024-08-02SaleCEO and President
981
0.0158%
$14.23$13,962+14.84%
2024-08-02SaleChief Manufacturing Officer
785
0.0127%
$14.23$11,173+14.84%
2024-07-05Purchase10 percent owner
4,438
0.063%
$12.52$55,5640.00%
2024-07-03Purchase10 percent owner
4,562
0.0636%
$12.29$56,0670.00%
2024-06-17Purchase10 percent owner
179,500
0.0002%
$0.00$180+4.55%
2024-05-23Saledirector
2,117
0.0389%
$14.93$31,615+4.41%
2024-05-23SaleCEO and President
549
0.0101%
$14.93$8,199+4.41%
2024-05-23SaleChief Manufacturing Officer
172
0.0032%
$14.93$2,569+4.41%
2024-05-23SalePrincipal Accounting Officer
24
0.0004%
$14.93$358+4.41%
2024-04-30SaleCEO and President
1,569
0.0292%
$12.71$19,937+24.28%
2024-04-30SaleChief Manufacturing Officer
1,255
0.0233%
$12.71$15,947+24.28%
2024-04-01Saledirector
1,206
0.0223%
$13.07$15,765+16.43%
2024-04-01SaleCEO and President
354
0.0065%
$13.07$4,627+16.43%
2024-04-01SaleChief Manufacturing Officer
197
0.0036%
$13.07$2,575+16.43%
2024-04-01SalePrincipal Accounting Officer
114
0.0021%
$13.07$1,490+16.43%
2024-03-27SaleCEO and President
392
0.0069%
$12.87$5,045+12.11%

Insider Historical Profitability

49.56%
GILEAD SCIENCES, INC.10 percent owner
1268972
19.964%
$14.5910
Schornstein Alexander10 percent owner
703113
11.0617%
$14.5970
Small Derek ACEO and President
669291
10.5296%
$14.5930<0.0001%
ELLISON RUSSELL HChief Executive Officer
58000
0.9125%
$14.5960+59.67%
BARRETT DAVID JONATHANChief Financial Officer
46980
0.7391%
$14.5930+85.85%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
The Vanguard Group$2.61M3.21196,368-91.61%-$28.5M<0.0001
Millennium Management LLC$1.66M2.04124,922-91.39%-$17.62M<0.01
BlackRock$1.04M1.2777,961-91.78%-$11.57M<0.0001
Geode Capital Management$694,371.000.8552,197-91.47%-$7.45M<0.0001
Acuitas Investments, LLC$661,436.000.8149,732-81.28%-$2.87M0.35
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.